drugset
drugset / Trial / NCT04547361

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

NCT04547361 ↗

Phase 1 Completed 45 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of E2511 following single ascending oral doses in healthy adult and elderly participants.

Timeline

Start
2020-09-14
Primary completion
2021-05-26
Completion
2021-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject E2511 Unknown — Oral

Indications

No indication recorded.